A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors

Investigational New Drugs

Volumn 32, Issue 5, 2014, Pages 937-945

  Cleary, James M ^a   Lima, Caio Max S Rocha ^b   Hurwitz, Herbert I ^c   Montero, Alberto J ^d   Franklin, Catherine ^e   Yang, Jianning ^e   Graham, Alison ^e   Busman, Todd ^e   Mabry, Mack ^e   Holen, Kyle ^e   Shapiro, Geoffrey I ^a   Uronis, Hope ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e ABBVIE INC   (United States)

Author keywords

ABT 263; Apoptosis; Bcl 2; Bcl xL; Gemcitabine; Navitoclax

Indexed keywords

ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; GEMCITABINE; NAVITOCLAX; PROTEIN BCL 2; SULFONAMIDE;

ADULT; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANILINE COMPOUNDS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84930745381     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0110-9     Document Type: Article

References (22)

1. Azmi AS, Mohammad RM (2009) Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol 218(1): 13-21
2. Del Gaizo Moore V (2008) and A. Letai, Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push? Adv Exp Med Biol 615:159-75
3. Kang MH, Reynolds CP (2009) Bcl-2 inhibitors: targetingmitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15(4):1126-32
4. Leibowitz B, Yu J (2010) Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol Ther 9(6):417-22
5. Tse C et al (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68(9):3421-8
6. Lin X et al (2006) /'Seed/' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2//Bcl- XL inhibitor ABT-737. Oncogene 26(27):3972-3979
7. Tahir SK et al (2007) Influence of Bcl-2 family members on the cellular response of small-cell Lung cancer cell lines to ABT-737. Cancer Res 67(3):1176-1183
8. Chen J et al (2011) The Bcl-2/Bcl-X (L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther 10(12):2340-9
9. Mini E et al (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17(5):7-12
10. Wong FY et al (2012) Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression. PLoS One 7(12):e50786
11. Schniewind B et al (2004) Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer 109(2):182-188
12. Okamoto K et al (2007) bcl-2-specific siRNAs restore Gemcitabine sensitivity in human pancreatic cancer cells. J Cell Mol Med 11(2): 349-361
13. Banerjee S et al (2010) Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells. Pancreas 39(3):323-31
14. Wong M et al (2012) Navitoclax (ABT-263) reduces Bcl-x (L)- mediated chemoresistance in ovarian cancer models. Mol Cancer Ther 11(4):1026-35
15. Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-47
16. Oken MM et al (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5(6): 649-55
17. National Cancer Institute. Common Terminology Criteria for Adverse Events, Version 3.0. 2006 [cited 2007 December 13]; Available from: http://ctep.cancer.gov/forms/CTCAEv3.pdf.
18. Roberts AW et al (2012) Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30(5):488-96
19. Wilson WH et al (2010) Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoidmalignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11(12):1149-59
20. Rudin CM et al (2012) Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 18(11):3163-9
21. Gandhi L et al (2011) Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29(7):909-16
22. Corcoran RB et al (2013) Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 23(1):121-8